Tirzepatide (Mounjaro, Zepbound) targets two pathways and tends to produce greater weight loss in head-to-head studiesroughly 20% body weight loss on tirzepatide vs 15% on semaglutide
Imagine Drucker submitting a grant proposal today titled "Investigating Gila Monster Venom Proteins for Potential Therapeutic Applications." How would reviewers respond to: Unclear commercial potential No obvious connection to existing treatment paradigms High risk of "failure" (most venom studies don't yield drugs) Difficult to measure short-term impact Traditional funding metrics, publication counts, citation indices, immediate clinical relevance, would likely work against such proposals
However, theyre not completely risk-free
The cost of lipotropic injections can vary widely depending on factors such as geographic location, provider experience, and specific ingredients used
Your medical records should be transferable to a new provider
ASL control (without labeling) and label images are then acquired after a post labeling delay (PLD), which allows the blood water to reach the brain tissue
